| ACE-I | Angiotensin-converting enzyme inhibitor |
| AD | Alzheimer’s disease |
| AKT | Protein kinase B |
| AMPK | Adenosine monophosphate-activated protein kinase |
| Bcl-2 | B-cell lymphoma 2 |
| BMC | Bone mineral content |
| BMD | Bone mineral density |
| CCC | Cholangiocellular carcinoma |
| CHD | Coronary heart disease |
| CKD | Chronic kidney disease |
| CNS | Central nervous system |
| cOC | Carboxylated osteocalcin |
| CRP | C-reactive protein |
| CV | Cardiovascular |
| CVD | Cardiovascular disease |
| dp-ucMGP | Dephosphorylated-uncarboxylated matrix Gla protein |
| Gas6 | Growth arrest-specific protein 6 |
| GGCX | Gamma-glutamyl carboxylase |
| Gla | γ-carboxylated glutamic acid |
| Glu | Glutamic acid |
| GRP | Gla-rich protein |
| HbA1c | Glycated hemoglobin |
| HCC | Hepatocellular carcinoma |
| HDL | High-density lipoprotein |
| HIF-1α | Hypoxia-inducible factor-1α |
| HOMA-IR | Homeostatic model assessment for insulin resistance |
| HR | Hazard ratio |
| IL | Interleukin |
| JNK | C-Jun N-terminal kinase |
| metS | Metabolic syndrome |
| MGP | Matrix Gla protein |
| MK | Menaquinone |
| mTORC | Mammalian target of rapamycin complex |
| NF-кB | Nuclear factor kappa-light-chain-enhancer of activated B cells |
| Nrf2 | Nuclear factor erythroid 2–related factor 2 |
| OA | Osteoarthritis |
| OC | Osteocalcin |
| OR | Odds ratio |
| OS | Oxidative stress |
| PCOS | Polycystic ovary syndrome |
| PD | Parkinson’s disease |
| PI3K | Phosphatidylinositide-3-kinase |
| PK | Phylloquinone |
| RCT | Randomized controlled trial |
| ROS | Reactive oxygen species |
| SIRT | Sirtuin |
| T2D | Type 2 diabetes |
| TNF-α | Tumor necrosis factor-alpha |
| tOC | Total osteocalcin |
| UBIAD1 | UbiA prenyltransferase domain containing 1 |
| ucMGP | Uncarboxylated matrix Gla protein |
| ucOC | Undercarboxylated osteocalcin |
| VC | Vascular calcification |
| vitD | Vitamin D |
| VK | Vitamin K |
| VKAs | Vitamin K antagonists |
| VKDP | Vitamin K-dependent protein |
| ACE-I | angiotensin-converting enzyme inhibitor |
| AD | Alzheimer’s disease |
| AKT | protein kinase B |
| AMPK | adenosine monophosphate-activated protein kinase |
| Bcl-2 | B-cell lymphoma 2 |
| BMC | bone mineral content |
| BMD | bone mineral density |
| CCC | cholangiocellular carcinoma |
| CHD | coronary heart disease |
| CKD | chronic kidney disease |
| CNS | central nervous system |
| cOC | carboxylated osteocalcin |
| CRP | C-reactive protein |
| CV | cardiovascular |
| CVD | cardiovascular disease |
| dp-ucMGP | dephosphorylated-uncarboxylated matrix Gla protein |
| Gas6 | growth arrest-specific protein 6 |
| GGCX | gamma-glutamyl carboxylase |
| Gla | γ-carboxylated glutamic acid |
| Glu | glutamic acid |
| GRP | Gla-rich protein |
| HbA1c | glycated hemoglobin |
| HCC | hepatocellular carcinoma |
| HDL | high-density lipoprotein |
| HIF-1α | hypoxia-inducible factor-1α |
| HOMA-IR | homeostatic model assessment for insulin resistance |
| HR | hazard ratio |
| IL | interleukin |
| JNK | c-Jun N-terminal kinase |
| metS | metabolic syndrome |
| MGP | matrix Gla protein |
| MK | menaquinone |
| mTORC | mammalian target of rapamycin complex |
| NF-кB | nuclear factor kappa-light-chain-enhancer of activated B cells |
| Nrf2 | nuclear factor erythroid 2–related factor 2 |
| OA | osteoarthritis |
| OC | osteocalcin |
| OR | odds ratio |
| OS | oxidative stress |
| PCOS | polycystic ovary syndrome |
| PD | Parkinson’s disease |
| PI3K | phosphatidylinositide-3-kinase |
| PK | phylloquinone |
| RCT | randomized controlled trial |
| ROS | reactive oxygen species |
| SIRT | sirtuin |
| T2D | type 2 diabetes |
| TNF-α | tumor necrosis factor-alpha |
| tOC | total osteocalcin |
| UBIAD1 | UbiA prenyltransferase domain containing 1 |
| ucMGP | uncarboxylated matrix Gla protein |
| ucOC | undercarboxylated osteocalcin |
| VC | vascular calcification |
| vitD | vitamin D |
| VK | vitamin K |
| VKAs | vitamin K antagonists |
| VKDP | vitamin K–dependent protein |